Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203972 | 0.90 | AR (0.44) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4207744 | 0.89 | AR (0.45) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL27376804 | 0.85 | AR (0.52) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4207181 | 0.78 | SLC6A4 (0.49) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4192800 | 0.76 | AR (0.52) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL20995920 | 0.76 | LMNA (0.52) | CYP2D6PPARGPPARA | |
| SCHEMBL13779687 | 0.73 | AR (0.59) | ARMRGPRX4 | |
| SCHEMBL4142305 | 0.72 | PPARG (0.56) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4157932 | 0.72 | PPARG (0.56) | ARMRGPRX4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4184922 | 0.72 | AR (0.65) | ARMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197642-A1 | Androgen modulators | WARNER-LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | claimed |
| US-7473711-B2 | Androgen modulators | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070197642-A1 | Androgen modulators | WARNER-LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | disclosed |
| EP-1740533-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005102990-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197642-A1 | Androgen modulators | CYP17A1, NR5A1, SHBG | AR 4/4885MRGPRX4 1177/4885CYP2D6 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.